Agios Pharmaceuticals, Inc.
🏢 View company profile →96Patents
96Active
96Granted
57Portfolio score
Filing activity: Jun 29, 2010 → Nov 10, 2023 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8742119B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | Chemistry; Metallurgy | 37 | Active |
| US8785450B2 | Therapeutic compounds and compositions | Emerging Cross-Sectional Technologies | 31 | Active |
| US8889667B2 | Therapeutic compounds and compositions | Chemistry; Metallurgy | 28 | Active |
| US9474779B2 | Therapeutically active compositions and their methods of use | Chemistry; Metallurgy | 26 | Active |
| US9108921B2 | Therapeutic compounds and compositions | Chemistry; Metallurgy | 21 | Active |
| US9512107B2 | Therapeutically active compositions and their methods of use | Chemistry; Metallurgy | 20 | Active |
| US9328077B2 | Bicyclic PKM2 activators | Chemistry; Metallurgy | 19 | Active |
| US8501953B2 | PKM2 modulators for use in the treatment of cancer | Chemistry; Metallurgy | 18 | Active |
| US9850277B2 | Therapeutically active compositions and their methods of use | Chemistry; Metallurgy | 17 | Active |
| US9458132B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | Chemistry; Metallurgy | 17 | Active |
| US8883438B2 | Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1 | Chemistry; Metallurgy | 16 | Active |
| US9221792B2 | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators | Human Necessities | 16 | Active |
| US9181231B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | Chemistry; Metallurgy | 15 | Active |
| US9579324B2 | Therapeutically active compounds and their methods of use | Chemistry; Metallurgy | 15 | Active |
| US9968595B2 | Pharmaceutical compositions of therapeutically active compounds | Chemistry; Metallurgy | 13 | Active |
| US9193701B2 | Pyruvate kinase activators for use in therapy | Chemistry; Metallurgy | 13 | Active |
| US9732062B2 | Therapeutically active compounds and their methods of use | Chemistry; Metallurgy | 11 | Active |
| US9199968B2 | Therapeutic compounds and compositions | Chemistry; Metallurgy | 11 | Active |
| US9656999B2 | Therapeutically active compounds and their methods of use | Chemistry; Metallurgy | 11 | Active |
| US9404081B2 | Pyruvate kinase activators for use in therapy | Chemistry; Metallurgy | 11 | Active |
| US9682080B2 | Pyruvate kinase activators for use in therapy | Chemistry; Metallurgy | 11 | Active |
| US9738625B2 | Therapeutically active compounds and their methods of use | Chemistry; Metallurgy | 11 | Active |
| US9694013B2 | Therapeutically active compounds and their methods of use | Human Necessities | 11 | Active |
| US9724350B2 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | Chemistry; Metallurgy | 10 | Active |
| US10610125B2 | Methods and compositions for cell-proliferation-related disorders | Emerging Cross-Sectional Technologies | 9 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.